GR3035662T3 - Escherichia coli o-polysaccharide-protein conjugate vaccine. - Google Patents

Escherichia coli o-polysaccharide-protein conjugate vaccine.

Info

Publication number
GR3035662T3
GR3035662T3 GR20010400512T GR20010400512T GR3035662T3 GR 3035662 T3 GR3035662 T3 GR 3035662T3 GR 20010400512 T GR20010400512 T GR 20010400512T GR 20010400512 T GR20010400512 T GR 20010400512T GR 3035662 T3 GR3035662 T3 GR 3035662T3
Authority
GR
Greece
Prior art keywords
polysaccharide
present
coli
vaccines
escherichia coli
Prior art date
Application number
GR20010400512T
Other languages
English (en)
Inventor
Stanley J Cryz
Emil P Furer
Original Assignee
Stanley J Cryz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanley J Cryz filed Critical Stanley J Cryz
Publication of GR3035662T3 publication Critical patent/GR3035662T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GR20010400512T 1991-08-12 2001-03-29 Escherichia coli o-polysaccharide-protein conjugate vaccine. GR3035662T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/743,787 US5370872A (en) 1991-08-12 1991-08-12 Escherichia coliO-polysaccharide-protein conjugate vaccine
PCT/US1992/006531 WO1993003765A1 (en) 1991-08-12 1992-08-11 Escherichia coli o-polysaccharide-protein conjugate vaccine

Publications (1)

Publication Number Publication Date
GR3035662T3 true GR3035662T3 (en) 2001-06-29

Family

ID=24990179

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010400512T GR3035662T3 (en) 1991-08-12 2001-03-29 Escherichia coli o-polysaccharide-protein conjugate vaccine.

Country Status (12)

Country Link
US (1) US5370872A (el)
EP (1) EP0598818B1 (el)
JP (1) JP2763960B2 (el)
AT (1) ATE198989T1 (el)
AU (1) AU669854B2 (el)
CA (1) CA2115564C (el)
DE (1) DE69231673T2 (el)
DK (1) DK0598818T3 (el)
ES (1) ES2154263T3 (el)
GR (1) GR3035662T3 (el)
WO (1) WO1993003765A1 (el)
ZA (1) ZA926063B (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
NZ269124A (en) * 1993-07-27 1997-06-24 Csl Ltd Vaccine comprising helicobacter antigens and its use in treating such infections
US6872398B2 (en) * 1995-12-22 2005-03-29 The United States Of America As Represented By The Secretary Of The Army Conjugate vaccine against gram-negative bacterial infections
SE9601158D0 (sv) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
AU1420897A (en) * 1996-12-18 1998-07-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Conjugate vaccine for (salmonella paratyphi) a
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US6749831B1 (en) * 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
CN1402786A (zh) * 1999-05-18 2003-03-12 衣阿华研究基金大学 复合糖的生产
US7749511B2 (en) 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
WO2001078787A2 (en) * 2000-04-18 2001-10-25 Endobiologics, Incorporated Lipopolysaccharide-conjugate vaccine for sepsis treatment
CA2459040A1 (en) * 2001-09-14 2003-03-27 Mimeon, Inc. Methods of making glycolmolecules with enhanced activities and uses thereof
WO2007078615A2 (en) * 2005-12-15 2007-07-12 Cavit Sciences, Inc Methods and compositions for treatment of cancer
CA2703621C (en) 2007-11-09 2022-03-22 The Salk Institute For Biological Studies Use of tam receptor inhibitors as antimicrobials
US9050283B2 (en) 2009-01-16 2015-06-09 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal Salmonella
ES2602108T3 (es) 2010-04-07 2017-02-17 Momenta Pharmaceuticals, Inc. Método para cuantificar glicoformas que contienen alta manosa
WO2012125553A2 (en) 2011-03-12 2012-09-20 Momenta Pharmaceuticals, Inc. N-acetylhexosamine-containing n-glycans in glycoprotein products
WO2013181575A2 (en) 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to denosumab
MX365331B (es) 2013-01-17 2019-05-29 Arsanis Biosciences Gmbh Anticuerpo específico contra e. coli mdr.
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
EP2996772B1 (en) 2013-05-13 2018-12-19 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US12103962B2 (en) * 2014-02-06 2024-10-01 X4 Pharmaceuticals (Austria) GmbH E. coli specific antibodies
CA2940547C (en) 2014-02-24 2021-01-05 Glycovaxyn Ag Novel polysaccharide and uses thereof
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
WO2019175147A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against intra-abdominal infections
US11260119B2 (en) * 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2020240075A1 (en) 2019-03-18 2021-10-14 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
EA202192390A1 (ru) 2019-03-18 2021-12-03 Янссен Фармасьютикалз, Инк. Биоконъюгаты полисахаридных о-антигенов e.coli, способы их получения и способы их применения
EP4090363B1 (en) 2020-01-16 2024-09-04 Janssen Pharmaceuticals, Inc. Fimh mutant, compositions therewith and use thereof
EP4277921A1 (en) 2021-01-12 2023-11-22 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
DK163176C (da) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst Ugiftig konjugatvaccine mod infektioner af pseudomonas aeruginosa- og escherichia coli- bakterier, fremgangsmaade til fremstilling heraf og anvendelse af vaccinen
US5034516A (en) * 1987-08-04 1991-07-23 University Of Ottawa Synthetic antigens of sialic acid and derivatives thereof
JPH0329196A (ja) * 1989-05-09 1991-02-07 Advanced Micro Devicds Inc センス増幅器

Also Published As

Publication number Publication date
CA2115564C (en) 2002-01-22
ATE198989T1 (de) 2001-02-15
ZA926063B (en) 1993-05-19
DE69231673D1 (de) 2001-03-08
US5370872A (en) 1994-12-06
ES2154263T3 (es) 2001-04-01
CA2115564A1 (en) 1993-03-04
EP0598818A4 (en) 1995-04-05
DK0598818T3 (da) 2001-03-19
EP0598818A1 (en) 1994-06-01
JPH06510530A (ja) 1994-11-24
DE69231673T2 (de) 2001-06-07
EP0598818B1 (en) 2001-01-31
JP2763960B2 (ja) 1998-06-11
WO1993003765A1 (en) 1993-03-04
AU669854B2 (en) 1996-06-27
AU2464192A (en) 1993-03-16

Similar Documents

Publication Publication Date Title
ZA926063B (en) Escherichia coli-polysaccharide-protein conjugate vaccine.
CA2647455C (en) Processes for the conjugation of poly n-acetylated glucosamine to a carrier protein
US4356170A (en) Immunogenic polysaccharide-protein conjugates
FI110164B (fi) Menetelmä oligosakkaridin valmistamiseksi depolymeroimalla antigeeninen polysakkaridi
EA020459B1 (ru) Иммуногенная композиция
CN105267974A (zh) 用于缀合疫苗的经过修饰的多糖
CA2450203A1 (en) Capsular polysaccharide solubilisation and combination vaccines
JPH11506491A (ja) 修飾したメニンゴコッカスのポリサッカライドを結合したワクチン
JP7439174B2 (ja) 免疫原性コンジュゲート及びその使用
AU7580787A (en) Lipopolysaccharides of reduced toxicity and the production thereof
KR102428253B1 (ko) 신규한 다당류-단백질 접합체 및 이의 제조방법
CA2297072A1 (en) Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
WO1998047530A3 (en) Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
JP2022513562A (ja) 肺炎連鎖球菌の精製された莢膜多糖
AU2004207647B2 (en) Conjugates obtained by reductive amination of serotype 5 pneumococcus capsular polysaccharide
KR950703361A (ko) 그룹 b 스트렙토코쿠스 ⅱ형 및 v형 다당류-단백질 결합 백신
Lambden et al. Synthesis of immunogenic oligosaccharide-protein conjugates from the lipopolyasaccharide of Neisseria Gonorrhoeae P9
JP2023537945A (ja) 出現血清型２４ｆを含む多価肺炎球菌複合糖質ワクチン
DE69713089T2 (de) Verfahren zur herstellung von immunoaktiven mittel und impfstoffe
KR970706845A (ko) 식물 또는 과실의 폴리사카라이드로부터 합성된 장티푸스 백신 및 그 제법(synthesis of typhoid fever vaccine from a plant or fruit polysaccharide)
Cryz et al. Escherichia coliopolysaccharide-protein conjugate vaccine
CN118203657A (zh) 一种多糖结合疫苗及其制备方法和用途
ES2135355A1 (es) Vacuna anti-vibrio anguillarum (gava-3) para la prevencion de la enfermedad vibriosis del rodaballo y peces salmonidos, y procedimiento de obtencion.
Arndt et al. Strategies for type-specific glycoconjugate vaccines of Streptococcus pneumoniae
Santana et al. 12.9 Polysaccharide-Based Vaccines

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees